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Caution in the Use
of Bromocriptine in
Peripartum Cardiomyopathy
It is premature to attribute the recovery of 2 “postpartum cardio-
myopathy” patients to the blocking effect of bromocriptine against
prolactin and to assign causal relationship of 16 kDa prolactin to
human peripartum cardiomyopathy (PPCM) (1,2).
Both patients in heart failure were treated with angiotensin-
converting enzyme (ACE) inhibitor and beta-blocker drugs with
apparent benefit possibly even before the use of bromocriptine.
Most recent studies show that when PPCM is diagnosed in a
timely fashion and treatment is instituted with diuretic, ACE-
inhibitor, and beta-blocker drugs almost everyone improves, al-
most everyone survives, and over 50% completely recover left
ventricular systolic function (3,4). Furthermore, the rate of recov-
ery in many conventionally treated PPCM patients is often very
comparable to that seen in the 2 cases reported, without bro-
mocriptine in the picture.
I urge attention to the issue of the role of prolactin-suppression
with bromocriptine in the development of PPCM through care-
fully controlled, randomly assigned, double-blinded placebo stud-
ies, after addressing the following issues:
1) Is it safe to use bromocriptine in the early postpartum period?
A number of reports indicate acute myocardial infarction has
complicated the use of bromocriptine in healthy mothers for
lactate suppression (5). What will be the short-term and
long-term effects of circumventing the important natural
effects of prolactin on the involution process of the post-
gravida uterus?
2) Are the reputedly abnormal 16-kDa and the naturally occur-
ring 23-kDa derivatives of prolactin metabolism harmful?
Have sufficient studies been accomplished to be reasonably
confident that is the case?
3) Is serum prolactin significantly elevated in PPCM patients
either antepartum or post-partum as compared with healthy
non-PPCM patients? If so, as might be the case because of
efforts to stimulate lactation in an acutely or subacutely ill
mother, does that elevation constitute a causal relationship to
PPCM rather than a non-causal physiological response?
It is also important to pursue these issues, because if third world
mothers with PPCM—where the incidence is higher—were to
inhibit lactation through the use of bromocriptine or simply cease
breastfeeding in an effort to eventually decrease prolactin, many of
their newborns would die of malnutrition as a consequence of the
inability to provide a substitute for breast milk (6).
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Reply
We have not made the claim that our 2 cases would establish
bromocriptine as a treatment for peripartum cardiomyopathy
(PPCM), and 2 clinical cases never prove a novel concept. We
stated this clearly and mentioned that the efficacy of bromocriptine
in treating PPCM patients has to be evaluated in a controlled
randomized clinical trial (1). Thus, we agree with Dr. Fett’s point
that these 2 case reports are no proof for a beneficial effect of
bromocriptine in PPCM, even though meanwhile we have made
similar beneficial observations in 5 additional patients, applying
the same protocol.
Concerning the safety of bromocriptine, there are in fact several
case reports on myocardial infarction in early post-partum women
in association with taking bromocriptine (2). However, there is a
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